Abiopharma

News list

(90% Positive) BioNTech SE (BNTX) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 5:37 p.m.
🌍 BioNTech SE (BNTX) - Form 6-K Filing

Filing Date: 2022-06-23

Accepted: 2022-06-23 16:34:09

Event Type: Clinical Trial Update

Event Details:

First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency. BNT211 combines two innovative approaches in one regimen, an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6)
💼 Business Developments:
- ❌ Partnership/Collaboration: Not reported
- ❌ Acquisition Activity: Not reported
- ❌ Licensing Agreement: Not reported
- ✅ Regulatory Milestone
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Email: Media@biontech.deInvestor